

# Integrated care for older multimorbid heart failure patients: protocol for the ESCAPE randomized trial and cohort study

Christine Zelenak<sup>1\*</sup>, Jonas Nagel<sup>1</sup>, Kristina Bersch<sup>2</sup>, Lisa Derendorf<sup>3</sup>, Frank Doyle<sup>4</sup>, Tim Friede<sup>5,6</sup>, Birgit Herbeck Belnap<sup>1,7</sup>, Sebastian Kohlmann<sup>8</sup>, Søren T. Skou<sup>9,10</sup>, Carlos A. Velasco<sup>11</sup>, Christian Albus<sup>12</sup>, Thomas Asendorf<sup>2</sup>, Christian Axel Bang<sup>13</sup>, Margarita Beresnevaite<sup>14</sup>, Niels Eske Bruun<sup>13,15</sup>, Matthew M. Burg<sup>16</sup>, Sussi Friis Buhl<sup>17</sup>, Peter H. Gæde<sup>18,19</sup>, Dagmar Lühmann<sup>20</sup>, Anna Markser<sup>12</sup>, Klaudia Vivien Nagy<sup>21</sup>, Chiara Rafanelli<sup>22</sup>, Sanne Rasmussen<sup>17</sup>, Jens Søndergaard<sup>17</sup>, Jan Sørensen<sup>23</sup>, Adrienne Stauder<sup>24</sup>, Stephanie Stock<sup>3</sup>, Stefano Urbinati<sup>25</sup>, Diego Della Riva<sup>25</sup>, Rolf Wachter<sup>26</sup>, Florian Walker<sup>2</sup>, Susanne S. Pedersen<sup>27,28</sup>, Christoph Herrmann-Lingen<sup>1,6</sup> and on behalf of the ESCAPE consortium

<sup>1</sup>Department of Psychosomatic Medicine and Psychotherapy, University of Göttingen Medical Centre, Göttingen, Germany; <sup>2</sup>Clinical Trial Unit of the University Medical Center Göttingen, Göttingen, Germany; <sup>3</sup>Faculty of Medicine and University Hospital of Cologne, Institute of Health Economics and Clinical Epidemiology, University of Cologne, Cologne, Germany; <sup>4</sup>Royal College of Surgeons in Ireland, Dublin, Ireland; <sup>5</sup>Department of Medical Statistics, University of Göttingen Medical Centre, Göttingen, Germany; <sup>6</sup>German Centre for Cardiovascular Research (DZHK), partner site Göttingen, Göttingen, Germany; <sup>7</sup>Center for Behavioral Health, Media, and Technology, Division of General Internal Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; <sup>8</sup>Clinic for Psychosomatic Medicine and Psychotherapy, University Hospital Hamburg Eppendorf, Hamburg, Germany; <sup>9</sup>The Research Unit PROgrez, Department of Physiotherapy and Occupational Therapy, Næstved-Slagelse-Ringsted Hospitals, Region Zealand, Slagelse, Denmark; <sup>10</sup>Research Unit for Musculoskeletal Function and Physiotherapy, Department of Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense, Denmark; <sup>11</sup>Fraunhofer Institute for Applied Information Technology FIT, Schloss Birlinghoven, Sankt Augustin, Germany; <sup>12</sup>Faculty of Medicine and University Hospital of Cologne, Department of Psychosomatics and Psychotherapy, University of Cologne, Cologne, Germany; <sup>13</sup>Department of Cardiology, Zealand University Hospital, Roskilde, Denmark; <sup>14</sup>Laboratory of Clinical Cardiology, Institute of Cardiology, Lithuanian University of Health Sciences, Kaunas, Lithuania; <sup>15</sup>Clinical Institutes, Copenhagen and Aalborg Universities, Copenhagen, Denmark; <sup>16</sup>Yale University School of Medicine, New Haven, CT, USA; <sup>17</sup>Research Unit of General Practice, Department of Public Health, University of Southern Denmark, Odense, Denmark; <sup>18</sup>Department of Cardiology and Endocrinology, Slagelse Hospital, Slagelse, Denmark; <sup>19</sup>Institute of Regional Health, University of Southern Denmark, Odense, Denmark; <sup>20</sup>University Hospital Hamburg Eppendorf, Hamburg, Germany; <sup>21</sup>Heart and Vascular Center, Semmelweis University Budapest, Budapest, Hungary; <sup>22</sup>Department of Psychology, University of Bologna, Bologna, Italy; <sup>23</sup>Healthcare Outcomes Research Centre, Dublin, Ireland; <sup>24</sup>Institute of Behavioural Sciences, Semmelweis University, Budapest, Hungary; <sup>25</sup>Bellaria Hospital and University of Bologna, Bologna, Italy; <sup>26</sup>University Hospital of Leipzig, Leipzig, Germany; <sup>27</sup>Department of Psychology, University of Southern Denmark, Odense, Denmark; and <sup>28</sup>Department of Cardiology, Odense University Hospital, Odense, Denmark

## Abstract

**ESCAPE** Evaluation of a patient-centred biopsychosocial blended collaborative care pathway for the treatment of multimorbid elderly patients.

**Therapeutic Area** Healthcare interventions for the management of older patients with multiple morbidities.

**Aims** Multi-morbidity treatment is an increasing challenge for healthcare systems in ageing societies. This comprehensive cohort study with embedded randomized controlled trial tests an integrated biopsychosocial care model for multimorbid elderly patients.

**Hypothesis** A holistic, patient-centred pro-active 9-month intervention based on the blended collaborative care (BCC) approach and enhanced by information and communication technologies can improve health-related quality of life (HRQoL) and disease outcomes as compared with usual care at 9 months.

**Methods** Across six European countries, ESCAPE is recruiting patients with heart failure, mental distress/disorder plus  $\geq 2$  medical co-morbidities into an observational cohort study. Within the cohort study, 300 patients will be included in a randomized controlled assessor-blinded two-arm parallel group interventional clinical trial (RCT). In the intervention, trained care managers (CMs) regularly support patients and informal carers in managing their multiple health problems. Supervised by a clinical specialist team, CMs remotely support patients in implementing the treatment plan—customized to the patients' individual needs and preferences—into their daily lives and liaise with patients' healthcare providers. An eHealth platform with an integrated patient registry guides the intervention and helps to empower patients and informal carers.

HRQoL measured with the EQ-5D-5L as primary endpoint, and secondary outcomes, that is, medical and patient-reported outcomes, healthcare costs, cost-effectiveness, and informal carer burden, will be assessed at 9 and  $\geq 18$  months.

**Conclusions** If proven effective, the ESCAPE BCC intervention can be implemented in routine care for older patients with multiple morbidities across the participating countries and beyond.

**Keywords** Blended collaborative care; Multi-morbidity; Heart failure; Depression; Psychological distress; Quality of life; Multinational trial

Received: 25 October 2022; Revised: 2 December 2022; Accepted: 9 January 2023

\*Correspondence to: Christine Zelenak, Department of Psychosomatic Medicine and Psychotherapy, University of Göttingen Medical Center, Von-Siebold-Str. 5, D-37075 Göttingen, Germany. Email: [christine.zelenak@med.uni-goettingen.de](mailto:christine.zelenak@med.uni-goettingen.de)

Registration: The study has been registered at the University of Göttingen Medical Centre (UMG Reg. No 02853) and the German Clinical Trials Register (DRKS00025120). Christine Zelenak and Jonas Nagel share first authorship.

Susanne S. Pedersen and Christoph Herrmann-Lingen share last authorship.

[Correction added on 30 March 2023, after first online publication: Affiliation 6 has been added to Tim Friede and Christoph Herrmann-Lingen; and the sequence for the rest of the affiliations were reordered accordingly.]



UNIVERSITÄTSMEDIZIN  
GÖTTINGEN : UMG

## Introduction: Background and scientific rationale

Heart failure (HF) affects over 64 million people worldwide<sup>1</sup> and is a major cause of mortality, morbidity, hospitalizations, and disability contributing to substantial healthcare costs across European countries (1–3% of all healthcare expenditure<sup>2</sup>). Its prevalence is particularly high in older adults, expected to further increase due to an ageing population,<sup>1</sup> and medical advances have not reduced its prevalence so far.<sup>3</sup> Furthermore, HF contributes significantly to a reduced health-related quality of life (HRQoL).<sup>1</sup> For abbreviations refer to *Table 1*.

In addition to problems directly related to HF, most HF patients suffer from somatic and mental multi-morbidity,<sup>4</sup> that is, the co-occurrence and possible interaction of multiple, usually chronic, somatic, and/or mental health conditions. Mental distress and disorders are known to interact with heart disease and other physical illnesses in a bidirectional way: They can be triggered or amplified by a physical disease and in turn impair patients' HRQoL and prognosis.<sup>5,6</sup> For example, in HF patients, depression can increase medical encounters, emergency room visits by twofold, hospital readmissions over 6–12 months by  $\geq 50\%$ , and total healthcare costs by 29%.<sup>7</sup> Mental co-morbidities also reduce the benefits of cardiac rehabilitation.<sup>8</sup> After coronary artery and heart valve surgery, anxiety and lower education are independent predictors of mortality and morbidity.<sup>9</sup> Patients with mental co-morbidity or distress are often challenged adhering to

the demanding treatment regimens<sup>10</sup> for multi-morbidity, and their clinical outcomes are compromised. Yet, mental co-morbidities often go undetected in clinical routine. Finally, multi-morbidity can also pose a psychological and financial strain on patients' informal carers and relatives.<sup>11</sup>

Continuous and timely care by physicians promotes patients' treatment adherence and can have a protective effect on mortality and rehospitalization.<sup>12</sup> However, healthcare providers often lack the time to address the complexity of multi-morbidity and its challenges, leading to a narrowed treatment focus, missed or delayed diagnoses, especially those pertaining to mental disorders, inappropriate prescribing and redundant diagnostics. Treatment of patients with multi-morbidity is typically coordinated by general practitioners (GPs) who are confronted with numerous problems.<sup>13</sup> Ineffective communication among providers including various specialists can result in fragmented care, especially if each provider focuses on isolated disease entities,<sup>4</sup> resulting among others in high treatment burden on patients<sup>6</sup> and polypharmacy that leads to adverse drug reactions<sup>14</sup> and drug–drug interactions causing avoidable hospital admissions.<sup>15</sup>

To address these treatment gaps and fragmented care, it is indispensable that patients with multi-morbidity receive integrated, patient-centred care across all conditions and specialties.<sup>6</sup> This is particularly relevant for patients with HF and mental co-morbidities, such as depression, as integrated care treatment of co-morbid mental disorders verifiably increases HRQoL<sup>16</sup> and reduces hospital readmissions of HF patients.<sup>17</sup>

One such integrated care model is collaborative care (CC), a team-based approach across providers. In the USA, CC effectively improved depressive symptoms in cardiac patients.<sup>18</sup> However, focusing CC primarily on depression treatment does not seem to render any viable somatic benefit.<sup>18,19</sup> Most relevant, the TeamCare trial, targeting both mental health and cardiovascular risk factors, showed that this 'blended' CC strategy (BCC) can improve both conditions<sup>20</sup> at no or minimal additional cost.<sup>21</sup> The Hopeful Heart trial<sup>16</sup> successfully employed the BCC intervention to treat depressive HF patients, but without explicitly addressing physical multi-morbidity or mental conditions besides depression.<sup>22</sup>

**Table 1** List of abbreviations

AE	Adverse event
(B)CC	(Blended) collaborative care
CEA	Cost-effectiveness analysis
CONSORT	Consolidated Statement of Reporting Trials
CRA	Clinical research associate
CTU	Clinical trial unit
CVD	Cardiovascular disease
DFD	Depression-free days
DSMB	Data Safety and Monitoring Board
eCRF	Electronic case report form
EOS	End of study
EOT	End of treatment
EQ-5D-5L	RQoL questionnaire w/5 dimensions developed by the EuroQoL Group
ESCAPE	Evaluation of a patient-centred biopsychosocial blended collaborative care pathway for the treatment of multimorbid elderly patients
EU	European Union
FAIR principles	Findable Accessible Interoperable Reusable
FU	Follow-up
GP	General practitioner
HADS	Hospital Anxiety and Depression Scale
HF	Heart failure
HRQoL	Health-related quality of life
ICP	Integrated Care Platform
ITT	Intention-to-treat
iMCQ	Medical Consumption Questionnaire
MAM	Meta-algorithm for multi-morbidity
CM	Care manager
PIC	Patient-informed consent
RCT	Randomized controlled trial
SAE	Serious adverse event
SOP	Standard operating procedure
UC	Usual care
UMG	Universitätsmedizin Göttingen/University Medical Center Göttingen

This table lists the abbreviations used in the publication of the ESCAPE study's protocol.

Despite these promising results, BCC interventions have not been tested in multi-morbid patients in Europe. To overcome this structural deficit, the ESCAPE consortium has received funding from the EU (EU Horizon 2020; project no. 945377) to develop and examine an integrated care concept for older patients with somatic-mental multi-morbidity. By introducing our integrated care concept, we extend previous concepts of multi-morbidity care to a vulnerable patient group with a high need for care integration. In particular, we chose to focus on patients with HF and somatic-mental multi-morbidity, given the high prevalence of HF in older adults and its frequent co-occurrence and interaction with other somatic<sup>3</sup> and mental<sup>5</sup> conditions.

ESCAPE strives to improve quality of care and HRQoL through the delivery of a personalized blended collaborative care (BCC) intervention, integrating a meta-algorithm for multi-morbidity to optimize patient-centred treatment plans<sup>23</sup> and supported by advanced information and communication technology. It also attempts to support the informal carers who are expected to benefit (i) emotionally from knowing that their relative has somebody to talk to concern-

ing both emotional and medical questions and (ii) practically by having somebody who coordinates all information relevant for the care of their relative, a task most informal carers have to do without any medical education in their spare time.

## Study objectives and design

The current paper describes, in accordance with the SPIRIT reporting guideline<sup>24</sup> and objectives and design of the ESCAPE study, a comprehensive cohort study consisting of a longitudinal observational study and an embedded randomized controlled assessor-blinded two-arm parallel group interventional clinical trial (RCT).

The RCT will examine the primary hypothesis that adding a 9-month optimized and targeted BCC intervention to usual care (UC) for older patients with multi-morbidity improves HRQoL more than UC alone. The parallel cohort will allow to assess the external validity of the RCT in terms of both baseline characteristics and outcomes and the extrapolation of the intervention effect to the 'real world'. It further reflects routine care and provides an opportunity to investigate prognostic factors for the natural disease course.

Approximately 450 patients with HF,  $\geq 2$  chronic somatic co-morbidities (i.e. multi-morbidity), and psychological distress or disorder will be enrolled in the study, 300 in the RCT plus 150 in the observational cohort (*Figure 1*).


Patients do not receive any direct remuneration or free medication for study participation. However, patients in the RCT have a 50% chance of getting assigned a personal CM from whom they receive emotional and practical support once or twice monthly over 9 months.

## Subject population, selection criteria, and recruitment process

Eleven clinical centres in six European countries will participate in the recruitment, intervention delivery, and blinded assessments from either cardiac units or out of community general practices (Germany: University hospitals of Göttingen, Cologne, Leipzig, Hamburg; Denmark: General Practice-University of Southern Denmark; Roskilde and Slagelse hospitals, Region Zealand; Ireland: Beaumont Hospital Dublin; Lithuania: University of Kaunas; Hungary: Semmelweis University Budapest; Italy: Bellaria Hospital Bologna).

The cohort study will include older patients ( $\geq 65$  years old, any gender) with any type of HF,  $\geq 2$  chronic somatic co-morbidities, and elevated psychological distress or diagnosed mental disorder(s) over a recruitment period of 12 months. For inclusion and exclusion criteria, see *Figure 1*. Regarding the diagnosis of HF, the most important information is the diagnosis confirmed by a cardiologist or internist in a written medical report. In case HF as such has not been mentioned

**Figure 1** ESCAPE study flow chart. A delay before inclusion into the randomized controlled trial was chosen to ensure that patients' somatic diseases are chronic and distress or mental disorders persistent. Patients will receive standard of care between initial screening and rescreening. n, number of people. Wording for patients: 'Scoping study' = for cohort, 'Core study' for RCT.



in any written document yet, we rely on the diagnostic criteria as specified in the current ESC guidelines<sup>3</sup> with information taken from written medical records and the patient. In order to assure a correct diagnostic procedure, a standard operating procedure for the diagnosis of HF has been developed. Throughout the study, patient contacts take place via telephone, video, or in person. The questionnaires and patient consent forms are sent out by post or handed out in person. For the questionnaires, web-based completion is offered as additional option after providing any patient who wishes so with a specific password for the database that enables them to see only those questionnaires related to themselves. There are three ways of recruitment in ESCAPE: (i)

hospital-based, (ii) identification by GP, and (iii) advertisement asking for self-referral. Interested patients are contacted by or actively contact a recruiter who ascertains eligibility for the cohort study. Potentially eligible patients are asked for their written patient informed consent (PIC1) to participate in the screening process and in the cohort study. Consenting and eligible patients are rescreened 2–2.5 months later. In the meantime, they receive standard care for their conditions. As transient psychological problems can be expected to have resolved, this approach will ensure that only patients with more persistent symptoms are included into the cohort. Therefore, only patients eligible at both initial screening and rescreening remain in the study. These

**Table 2** Psychometric battery and data collected at the different visits

	Instrument	Category of information
Screening	Inclusion/exclusion criteria	
	Current diagnoses (ICD)	
	Hospital Anxiety and Depression Scale (HADS, 14 items)	Anxiety, depression, distress
Patient characteristics	Medical history and information extracted from medical records	
	Demographic variables	
	Barthel index, <sup>25,26</sup> 10 items	Physical/cognitive status, adherence, exercise
Tests	MoCA blind (mild cognitive impairment, 15 items) <sup>27</sup>	
	30-sec chair stand test (30s-CST, 1 item) <sup>28</sup>	
Self-report	EQ-5D-5L (incl. EQ-VAS + verbal explanation, 6 items) <sup>29,30</sup>	Quality of life
Questionnaires for patients	Kansas City Cardiomyopathy Questionnaire (KCCQ-12, 12 items) <sup>31</sup>	
	Global Perceived Effect on Quality of life, <sup>32,33</sup> 1 item	
	Self-reported frailty <sup>34</sup> –5 items	Physical/cognitive status, adherence, exercise
	Subjective self-report questions on cognitive impairment, <sup>35</sup> 2 items	
	PROMIS Physical Function Short Form 4, <sup>36</sup> 4 items	
	Brief version of the International Physical Activity Questionnaire for the elderly (IPAQ-E, 7 items) <sup>37</sup>	
	Medication Adherence Report Scale (MARS-5, 5 items) <sup>38</sup>	
	Table of medical conditions (respecting and allowing calculation of comorbidity burden using the Charlson Co-morbidity Index <sup>39,40</sup> and incl. NYHA, <sup>41</sup> 39 items)	Medical conditions and symptoms incl. CMSAS
	Table of symptoms _ respecting Charlson Comorbidity Index (CMSAS, 21 items)	
	Mental health symptoms (Patient Health Questionnaire-4, PHQ-4, 4 items) <sup>42</sup>	
	Medical Consumption Questionnaire (iMCQ) <sup>43</sup> plus 5 items of Productivity Cost Questionnaire (iPCQ), <sup>44</sup> 36 items	Cost-effectiveness and cost-utility
	Questionnaire on perceived social support (ESSI, 5 items) <sup>45,46</sup>	Moderators: Resources and loneliness
	UCLA Three-Item Loneliness Scale, <sup>47,48</sup> 3 items	
	General Self-Efficacy Scale (GSE, 3 items) <sup>49,50</sup>	
	Spirituality (FACIT Sp-12, 12 items) <sup>51</sup>	
	BRIEF Health Literacy Screening Tool, <sup>52</sup> 4 items	
	Patient Acceptable Symptom State (PASS, 2 items) <sup>32,33</sup>	Moderators: Illness perception and expectations
	Illness Perception Questionnaire (Brief IPQ, 9 items) <sup>53</sup>	
	Treatment expectations (TEX-Q short form, 6 items) <sup>54</sup>	
	Multimorbidity Treatment Burden Questionnaire (MTBQ, 10 items) <sup>55</sup>	Stress and treatment burden
	Perceived Stress Scale (PSS-4, 4 items) <sup>56,57</sup>	
	Quality indicators for quality of care, 12 items	
	Patient satisfaction questionnaire (custom), 4 items	Assessment of BCC-intervention aspects
	Working Alliance Inventory (WAI), <sup>58</sup> 12 items	
Questionnaires for informal carers	Carer QoL 7D, <sup>59</sup> 7 items	
	EQ-5D-5L (incl. EQ-VAS + verbal explanation, 6 items) <sup>29,30</sup>	
	Caregiver Burden Inventory (CBI, 24 items) <sup>60</sup>	
	Carer Satisfaction with Treatment (custom) - 4 items	
	Satisfaction with Life Scale (SWLS, 5 items) <sup>61</sup>	
	UCLA Three-Item Loneliness Scale, 3 items <sup>47,48,62</sup>	
	Perceived emotional social support (ESSI, 5 items) <sup>45,46</sup>	
Questions for GPs	Quality indicators for quality of care, via online survey, 12 items	

EOT, end of treatment; FU, follow-up; GP, general physician; RA, research assistant; SN, study nurse.

This table lists the data collected in the ESCAPE study and the instruments and means used for data collection.

Care managers can do the baseline assessment; however, as they are not blinded they cannot do the EOT and FU assessments. Questionnaires will be sent to the patients, SN/RA will fill in the remaining points together with the patient at the phone/video visit.

estimated 450 patients receive the set of baseline questionnaires (see *Table 2*) plus subsequent telephone or video interview. In addition, more details on their medical status will be obtained from the treating physicians (especially GP and/or hospital) and/or electronic medical records (EMR). After the baseline assessment, patients will be invited to participate in the embedded RCT and, if consenting, sign a second informed consent (PIC2). Those who decline RCT participation remain in the cohort. We will continue screening until we reach  $n = 300$  patients in the RCT and approximately  $n = 150$  in the cohort. Optimally, one informal carer per patient will additionally participate, recruited after the baseline visit has been performed.

To ensure timely recruitment and enhance recruitment efficiency, recruiters receive comprehensive training (see previous studies<sup>63,64</sup>). Agreements about recruitment targets and milestones have been established with each recruiting site.

## Study procedures

Patients randomized to the intervention group receive the ESCAPE BCC intervention in addition to their UC by physicians and others. Patients randomized to the control group and those remaining in the cohort receive UC for all their conditions and a leaflet summarizing their individual psychosocial, behavioural, and medical risk factor status but no other study-specific intervention. In addition, all patients in cohort and RCT receive access information to online health content on the ESCAPE website (see below) with Internet-based information (or directions) relevant for life with and treatment of their diseases.

Main assessments will take place for all patients at baseline, 9 months [end of treatment visit ('EOT')], and 18–33 months [follow-up (FU)], depending on date of recruitment (*Table 3*). Prior to the visits, patients are asked to fill in psychological questionnaires, online or mailed with paper/pencil, and to provide (possibly via GP or EMR) recent medical documents. The assessors ascertain completeness of the self-report data during the subsequent telephone interview belonging to the visit and ask for medical history, adverse events and healthcare utilization since the last visit. Assessment of medical status and risk factors at baseline is based on self-report and information from the GP, hospital, and/or EMR, as applicable.

Additionally, informal carers of all patients, if possible, are asked for their informed consent and assessed at baseline and month 9 (EOT).

For patients who withdraw their consent for study participation, the study site or the initiator of the trial will request information on the survival status and—if applicable—date of death from the GP, a relative, or the residents' registration office at the end of the trial.

## BCC intervention

The ESCAPE intervention is based on the BCC concept: a patient-centred team-based treatment strategy that promotes proactive, timely follow-up and support by a trained care manager (CM). The ESCAPE BCC strategy combines the framework from US trials<sup>20,22,65,66</sup> with own experiences from German multiprofessional psychosomatic treatment,<sup>67</sup> family medicine,<sup>68</sup> and cardiac rehabilitation.<sup>69</sup> It also incorporates experiences from the ongoing TEACH trial,<sup>70,71</sup> testing a BCC intervention in German patients with coronary heart disease, elevated distress levels, and insufficiently controlled cardiovascular risk factors. Before the beginning of the trial, we involved patients and their informal carers and patient-representative organizations based on a participatory design in the development of trial protocol, choice of questionnaires, and the BCC intervention<sup>72,73</sup> and tested the practicability in a small feasibility study.

After the patient's automated randomization to the intervention group, an electronic record is automatically created in the care management 'registry' with all relevant medical, psychological, and sociodemographic information collected at the RCT baseline assessment. To prevent unblinding of blinded personnel (study physician, follow-up assessors), the sites CM(s) receive(s) an email to be informed about the allocation. The CM subsequently contacts the patient to explore their treatment preferences and barriers. All CM–patient conversation takes place via telephone or video-call. Based on a meta-algorithm for multi-morbidity (MAM),<sup>23</sup> the CM collects any pertinent medical information that is then sent to the patient's GP who corrects, expands, and confirms the information and suggests a treatment plan considering current guidelines, the patient's medical history, preferences, values, and life goals. Critical signs or symptoms for severe health conditions, that is, so-called 'red flags', as, for example, angina pectoris, ankle oedema, or breathlessness, which should be regularly monitored, are highlighted. Subsequently, the CM and the patient agree in a shared decision manner<sup>74</sup> on two to three goals in alignment with the treatment plan, for example, increase physical activity and self-monitoring of weight gain. During the next months, the CM regularly contacts the patient to educate them about the conditions and treatment and monitor bothersome symptoms and 'red flags'. They provide support in goal attainment and integration of health behaviour and self-management into the patient's daily routine crucial for secondary prevention. They impart skills to cope with psychological burden, communicate across providers, and may encourage using community resources. CMs ensure that treatment agreements are followed and patients make progress with respect to their goals. If the patient so wishes, CMs also include informal carers in the discussion and support of patients' goals. CMs collaborate closely with their patients' GPs and update them on their patients' progress at regular intervals.

**Table 3** Visit schedule and assessments

PERIODS	Prescreening <sup>a</sup> and registration	Screening	Rescreening	Rescreening	Baseline $\pm$ randomization ('V0')	End of treatment ('V-EOT')	Follow-up <sup>f</sup> ('V-FU')
Time from baseline	-3 mo ( $\pm$ 2 weeks)	14 days ( $\pm$ 2 weeks)	Day 0	+9 mo ( $\pm$ 2 weeks)	+18 to 33 mo ( $\pm$ 2 weeks)		
RCT							
Cohort	x	x	x	x	x	x	x
Letter from GP to patient to initiate contact (subgroup only)	x	x	x	x	x (no randomization)	x	x
PIC 1 - screening process and cohort		x					
PIC 2 - RCT					x		
PIC 3 - for informal carer					x		
Current diagnoses	x	x <sup>a</sup>	x <sup>a</sup>	x <sup>a</sup>	x <sup>a</sup>	x <sup>a</sup>	x <sup>a</sup>
HADS, risk factors, inclusion and exclusion criteria		x	x	x	x <sup>b</sup>		
Demographics of patient and informal carer					x	x	x
Medical history incl. cardiovascular and behavioural risk factors, treatment, and medication					x	x <sup>a</sup>	x <sup>a</sup>
Self-report questionnaires for patients incl. HADS					x <sup>c</sup>	x <sup>c</sup>	x <sup>c</sup>
Questionnaires for informal carer					x	x	
Randomization					x		
Adverse events <sup>d</sup>					x	x	x
Feedback on RCT (patient and carer)					x	x	x

EOT, end of study treatment; FU, follow-up; GP, general practitioner; mo, month/s; PIC, patient-informed consent; RCT, randomized controlled trial.

This table gives an overview over the time schedule of the ESCAPE study.

<sup>a</sup>Full medical history incl. diagnoses and demographics will be obtained at baseline only. Only relevant changes from baseline will be documented during later assessments.

<sup>b</sup>In case of a baseline visit >2 weeks after rescreen, the HADS risk factors and inclusion and exclusion criteria will be repeated.

<sup>c</sup>Psychometric battery: see Table 2

<sup>d</sup>Severe intercurrent medical events have to be documented as SAEs in the eCRF as outlined in section 16.

<sup>e</sup>Prescreening on cardiology wards will be a personal contact visit, all other visits will be performed via phone or video call.

<sup>f</sup>Data on intervention participation and process measures obtained during care management (intervention group only) will not be documented in the eCRF but in a separate pseudonymized registry. At the end of the study, these data will be converged with the trial database.

The CMs contact their patients as part of the intervention over 9 months, approximately two calls per month during the first 3–4 months, later one call per month. They alert GPs immediately if any concerning or safety issues arise and update the GPs on the patients' progress regularly. At each patient contact, the CM enters relevant patient information to document progress and critical medical changes (e.g. red flags, worsening of symptoms, hospitalizations, changes in medications, vital symptoms, or lab results) into the registry (see below), which serves to guide CMs through their patient contacts. The registry is also used to document MAM feedback by the GP and to incorporate all relevant medical information, treatment plans, and personalized goals and to facilitate the standardization of CM-patient encounters across all sites.

A **clinical specialist team** for each country consisting of a GP, cardiologist, pharmacist/clinical pharmacologist, and a mental health specialist (psychologist/psychosomaticist/psychiatrist) supervises the CMs and makes treatment recommendations. During regular (online) **case review meetings**, the CMs present their patients to the clinical specialist team using the care management registry. The clinical specialist team (i) oversees that patients receive evidence-based treatment for all their conditions and distress and the initial patient-centred treatment plan is followed; (ii) assists CMs in addressing treatment barriers and supporting the patient and carer with their behavioural changes; and (iii) makes guideline-based treatment recommendations and monitors for possible negative effects of polypharmacy or drug–drug interactions. After a discussion, one or more recommendations are formulated that may pertain to (i) suggestions for clinical clarification, (ii) adjustments in pharmacotherapy according to STOPP/START2 criteria,<sup>75</sup> and (iii) any interventions directly delivered or encouraged by the CM. Afterwards, the CM discusses the recommendations with the patient and carer and informs the GP. The GP remains responsible for the patient's care and can decline or modify the specialist team's recommendations. An international specialist team will meet once a month with a designated representative from each local specialist team to discuss specific medical, psychological, or procedural and protocol questions. In addition, CMs and specialist teams can communicate to discuss with the international specialist team to ensure consistency across all sites.

**CMs** have an officially recognized training as healthcare professionals with experience in patient care in general practice, mental health services, or cardiology. They must be able to work in a team. At the beginning of the trial, all CMs participated in several training sessions where they were instructed in the components of care management, communication skills including shared decision-making, motivational interviewing, and problem-solving techniques<sup>76</sup> and the use of the MAM and the registry.

Furthermore, there will be regular refresher trainings that incorporate frequent questions, barriers, and reinforcement

of communication skills. Before the start of the trial, we developed a standardized intervention manual and CM training materials adapted from materials published with earlier studies<sup>18,20</sup> or developed during our own studies<sup>22,70,71</sup> and an ESCAPE feasibility trial. The intervention manual adhering to TIDieR guidelines<sup>77</sup> will be published separately including detailed standard operating procedures (SOPs) and training materials for CMs and treatment teams available in all languages. The materials will be regularly updated based on the requirements of the various healthcare systems and necessary adaptations during the intervention phase to ensure cohesiveness across clinical practices and to allow for later widespread implementation.

To ensure the fidelity of the BCC intervention, we will use the National Institute of Health Behaviour Change Consortium Framework (NIH BCC)<sup>78,79</sup> that includes five domains of treatment fidelity (Study Design, Training, Delivery, Receipt, Enactment). Hence, for each patient, we will collect detailed information on type and content of treatment, length of contact, duration of contact over time, etc. This information will be combined with the effectiveness data to (i) identify moderators and mediators of treatment effectiveness, (ii) update and validate quality indicators for multi-morbidity care, (iii) identify barriers to treatment, and (iv) inform implementation across various healthcare systems.

## UC

Due to the international nature of the ESCAPE trial, UC varies across the sites. For all sites, UC is based on national and/or European guidelines for all relevant conditions. Typically, UC entails follow-up at the GP, though some patients are also seen by specialists in private practice or in the hospitals' specialist clinics or departments.

## Measures

Baseline and follow-up medical information is obtained from detailed patient interviews and medical reports, from which diagnoses and disease severity information (such as echocardiographic measures of systolic and diastolic cardiac function, natriuretic peptide levels, etc.) are documented if available. During the visits, we question the patients with regard to their NYHA class.

All self-rating scales have been validated in at least one language. Validated translations are used as far as possible and will be scored objectively by established algorithms reported in the literature. For rating scales without validated local-language version, translations were made using the EU-translator programme<sup>80</sup> combined with review of the translation by the local investigators and a test of the translated version with two to three native speakers to assure



correct understanding (translated versions are available from the first author on request).

**HRQoL** is the **primary outcome**. HRQoL is a comprehensive patient-centred measure of subjective health, covering the overall impact of somatic and mental health conditions on patients' lives. HRQoL is recommended as a core outcome for several chronic conditions and constitutes a main component of the Core Outcome Set for Multimorbidity Research.<sup>81</sup> It is particularly well suited for evaluating the BCC approach in ESCAPE that addresses the whole range of multi-morbidity that is not reflected sufficiently in any single biomarker or specific symptom scale.

The **EQ-5D-5L**<sup>29,30</sup> will be used to measure overall HRQoL. The EQ-5D-5L index (primary outcome) covers the dimensions mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. It has been used in numerous studies across Europe, including in multi-morbid<sup>82,83</sup> and elderly<sup>84,85</sup> populations. It has been validated in numerous languages, shows acceptable sensitivity to change, and can also be used to evaluate cost-effectiveness. The EQ-5D-5L also includes a visual analogue scale (EQ-VAS, 0–100) to measure the global subjective health status, which will be used to determine a study-specific cut-off for minimal important change for specific scores and estimate the number of patients per group that has experienced a clinically important improvement.<sup>32,33</sup> To assess **QoL aspects specifically related to life with HF**, we will use the Kansas City Cardiomyopathy Questionnaire (KCCQ-12).<sup>31</sup>

Using the **Hospital Anxiety and Depression Scale (HADS)**,<sup>86,87</sup> we will assess patients' levels of psychological distress. The HADS has been used in numerous medical studies, including patients with heart disease<sup>88</sup> and yields separate scores for anxiety and depression. The total score (range 0–42) serves as accepted measure of overall psychological distress; a score >12 is expected to detect at least mild levels of distress shown to be prognostically relevant.

The **secondary outcomes** will cover objective medical endpoints, resource use and costs (for analysis of cost-effectiveness and cost utility), patient- and carer-reported outcomes covering specific areas of functioning, activity and well-being, and information about mediating and moderating factors. For details, see *Table 2* and *Appendix S2*.

Outcome variables from the clinical study will be used to validate the quality indicators describing the quality of care for patients with multi-morbidity proposed by the MULTIqual project.<sup>89–91</sup> The indicators capture whether and to what extent care processes with relevance to multi-morbidity have been implemented.

## Trial status

Between September 2021 and June 2022, nine patients participated in a feasibility study in Göttingen involving the work

groups responsible for organizing the RCT and for developing the BCC intervention, the local CM, and the German specialist team. Qualitatively, the study procedures appeared feasible, and the patients reported they benefited from the intervention.

Recruitment for the ESCAPE main study started at the coordinating site in Göttingen, Germany, in April 2022 with other sites following in subsequent months. The first patient was randomized in July 2022.

## Patient data storage and protection

Documentation of patient data will be handled according to the regulations outlined in the CONSORT statement.<sup>92</sup> Patient and informal carer data necessary for study evaluation are entered through an electronic case report form (eCRF) and stored in a GCP-compliant secuTrial® database. For details, see *Appendix S2*.

The intervention is supported by the **imergo® e-health Integrated Care Platform (ICP)** developed by the Digital Health department of the Fraunhofer Institute for Applied Information Technology FIT. For an impression of imergo®, see *Figure 2*; for more details, see *Appendix S2*.

## Quality control and monitoring

A **Data Safety and Monitoring Board (DSMB)** monitors the course of the study and can give a recommendation for study discontinuation, modification, or continuation. The principles for the DSMB are ethical and safety aspects for patients.

Quality control and quality assurance are ensured through **monitoring** according to ICH/GCP and internal SOPs following a risk-adapted and study specific monitoring strategy. For complete information, see *Appendix S2*.

## Ethical and regulatory requirements

The study is conducted according to the Declaration of Helsinki. All patients and informal carers receive written information about the study describing the cohort study and the RCT and will only be included into the trial upon their written consent. The **informed consent** forms (PIC1: consent for screening and cohort; PIC2: consent for RCT; PIC3: consent for carer assessments) and the study protocol (current version in Göttingen V1.2/16 February 2022, No. 02853)

**Figure 2** Presentation of the imergo® Integrated Care Platform: overview page for an individual patient.

The screenshot displays the ESCAPE Clinician Dashboard. At the top, there is a navigation bar with 'HOME', 'EN', user profile, chat, and 'LOGOUT' buttons. The main content area is titled 'Patient Overview' and is divided into four columns: Core Data, Monitor, Comorbidities, and Patient Preferences. Below these columns are buttons for 'Next Appointment', 'ADD NEW VISIT/CONTACT', 'PATIENT QUESTIONNAIRE', and 'SUICIDE PROTOCOL'.

**Core Data:**

- ID: 10927e10-73f8-5fbd-a011-97594de922a
- Clinical Study ID: ESC\_FhG\_013745
- Age: 92
- Gender: male
- Marital Status: Never Married
- Deceased: -
- Country: DE
- Clinical Study Status: Active
- Randomization date: 2022-06-10
- Member Testing: [Text input field]

**Monitor:**

- Clinical Impression: -
- Goal Attainment: -
- Red Flags: 4
- Cardiac ejection fraction: 40-49%
- NYHA class: -
- HADS anxiety score: 1
- HADS depression score: -
- PSS score: -
- Medical Adherence (MARS-5): 21
- Suicide protocol: No

**Comorbidities:**

- Heart failure [I50.9]
- Cardiac Arrest [I46.9]
- COPD - Chronic obstructive pulmonary disease [J44.9]
- Lung cancer [C34.9]

**Patient Preferences:**

- Walk 10 minutes in garden [Requested]
- Some - emo5 [Patient]
- Walk the dog 3 times daily [GP]

**Overview contacts:**

According to the FHIR standard, this term is characterized by the setting in which the encounter takes place. Amongst them are ambulatory, emergency, home health, inpatient and virtual encounters.

Descriptio n	Start Date	Status	General clinical im- pression score	Goal at- tainment score	# Red flags	Distress score*	PHQ-4 score*	Actions
Scheduled contact	2022-09-14	In Progress	-	-	0	Not Assessed	Not Assessed	[Refresh] [Edit]
Scheduled contact	2022-08-29	In Progress	-	-	0	Not Assessed	Not Assessed	[Refresh] [Edit]
Scheduled contact	2022-07-04	In Progress	-	-	0	Not Assessed	Not Assessed	[Refresh] [Edit]

have been approved by the responsible ethics committees of all participating study sites before inclusion of the first patient.

## Adverse events and risks of participation in the trial

BCC as addition to standard care has been tested in several RCTs, and implementation studies in the USA have demonstrated safety and acceptance.<sup>20,21</sup> No differences in SAE or re-hospitalization rates between BCC and UC groups have

been found in previous studies.<sup>16,20</sup> Therefore, we do not anticipate relevant study-specific risks for the patients. For details, see *Appendix S2*.

## Statistical analysis

Patients are allocated to intervention using a 1:1 allocation ratio. The randomization procedure is stratified by gender, frailty, and country and based on permuted blocks of varying length and implemented within the secuTrial® platform.

## Sample size calculation

A sample size of 130 patients per group yields a power of 80% at the usual two-sided significance level of 5% given a standardized treatment difference (Cohen's *d*) of 0.35. The assumed treatment difference is supported by a meta-analysis of RCTs testing collaborative care for depression in patients with heart disease that found the interventions effective for improving depressive symptoms [standardized mean difference (SMD) = -0.31], anxiety (SMD = -0.36), and mental QoL (SMD = +0.23). Furthermore, the only RCT using the EQ-5D as measure of global HRQoL in a collaborative care trial with cardiac patients<sup>93</sup> found an effect size of 0.34. Adjusting for premature discontinuation of the study by about 15% of the patients over a period of 9 months from randomization, we aim to recruit a total of 300 patients into the RCT. Based on the literature and experiences from clinical trials conducted at the participating sites, we estimate that about 40% of the patients in the initial cohort will be eligible with about two-thirds of those eligible after the second screening deciding to participate in the RCT.<sup>70,94,95</sup> Therefore, we anticipate that we need an initial cohort size of about 750 patients with approximately 450 patients remaining for long-term follow-up, including 300 patients willing to be randomized into the RCT.

## Methods of analysis

The primary analysis of the RCT will follow the intention-to-treat (ITT) principle. The primary endpoint will be analysed using an analysis of covariance (ANCOVA) with baseline assessment of the primary outcome as covariate and stratification variables of the randomisation as factors. Missing data will be dealt with by multiple imputation. The analyses of the secondary endpoints will follow the same lines as the analysis of the primary endpoint, where appropriate. Recurrent events, such as hospitalizations, will be modelled by negative binomial regression accounting for between-patient heterogeneity and varying follow-up length of up to 30 months. Time to event outcomes such as death will be analysed using Cox proportional hazards models. Pre-planned subgroup analyses will include analyses by gender and frailty status. Sensitivity analyses will explore potential clustering (by CM) effects in hierarchical (multilevel) models.

Because the RCT is embedded in a cohort study, the external validity of the RCT can be assessed in terms of both baseline characteristics and outcomes.<sup>96</sup> In addition, the cohort will allow the extrapolation of the intervention effect to the 'real-world' cohort reflecting routine care using the framework of a Bayesian hierarchical model.<sup>97</sup> Furthermore, the cohort provides an opportunity to investigate prognostic factors for the natural disease course using regression models appropriate for the outcome scale. Details of the statistical

analysis will be prespecified in a statistical analysis plan, which will be finalized prior to end of recruitment.

For the **health economic evaluation**, objective outcomes of interest will be verified by patients' medical records, health insurance data or self-report questionnaires for patients (iMCQ). A cost-effectiveness analysis (CEA) and a cost utility (CUA) will be performed with sub-group analyses for (i) depression vs. no depression and (ii) cardiovascular disease (CVD) vs. no CVD co-morbidities. Because benefit of the BCC approach in terms of HRQoL might not be reflected in a gain of quality-adjusted life years, country-specific CEA will be performed for countries with data on costs for a sufficient number of patients per group. The incremental cost-effectiveness ratios (ICER) will be calculated from a payer perspective. For patients with symptoms of depression, the costs per depression-free days (DFD) will be calculated with DFDs obtained using the iMCQ and HADS. For all patients, cost-effectiveness will also be measured in costs per avoided hospital admission. CUA will be calculated for specific countries using costs per QALY obtained from EQ-5D-5L taking into account different valuation algorithms.

## Discussion

ESCAPE has developed an adapted biopsychosocial BCC intervention for older patients with somatic-mental multi-morbidity and will examine its impact of patients's HRQoL compared with UC. The intervention extends research on HF case management<sup>98</sup> or BCC interventions for patients with cardiac-mental co-morbidity<sup>16,20</sup> to a highly vulnerable patient group in advanced age and with multiple physical and mental conditions. By fostering collaborations between patients and their informal carers, GPs, and treating medical specialists, ESCAPE offers a framework for addressing the complexity of multi-morbidity and its treatment in a team-based, patient-centred approach that overcomes paralleled single condition care. A recently developed meta-algorithm for multi-morbidity will support a targeted treatment plan developed through shared decision-making and integrating guideline-based treatment targets and patient preferences. The specifically designed imergo® patient registry with CM dashboard provides an infrastructure for handling the complex medical and psychosocial data needed for personalized recommendations and real-time support and monitoring of the treatment progress. Regular case reviews by multidisciplinary clinical specialist teams guarantee guideline adherence, goal attainment, and treatment fidelity. By adding pharmacological expertise to the specialty team, inappropriate prescribing and drug-drug interactions can be minimized. An overarching BCC approach will harmonize the work of local specialist teams including a pharmacist and add expertise in additional medical areas.

Patients will thereby receive integrated treatment advice based on the best available evidence and their personal preferences, values, and life goals. They will receive reliable support for living with the physical and mental challenges of multi-morbidity, empowering them for improved self-management, disease coping, and utilization of community resources. Formal and informal carers are supported in caring for the complex needs of the patients and communicating with each other.

Taken together, the ESCAPE approach is intended to improve the quality of life of both patients and informal carers and the quality of care delivered by the treating physicians, leading to improved health outcomes and potentially cost savings to society. If proven successful, ESCAPE will provide recommendations and pathways adaptable for routine care, which could guide updates of existing guidelines to facilitate implementation across Europe. Our results could serve as a model for the treatment of various multi-morbidities. Nevertheless, varying UC across sites due to the international nature of the ESCAPE trial, an inhomogeneous population due to various recruitment pathways in different countries and varying compositions of diseases in multi-morbid patients will challenge the proof of concept. This challenge however has a great potential and the chance to develop a differentiated team-based treatment approach for patients with multi-morbidity and their carers, which may be useful for broad patient populations across various countries and healthcare systems.

## Acknowledgements

Open Access funding enabled and organized by Projekt DEAL.

## Conflict of interest

The following authors declare conflicts of interest: Christoph Herrmann-Lingen, Susanne S. Pedersen, Søren T. Skou, Christian Albus, Dagmar Lühmann, Tim Friede, Niels E. Bruun, Jens Søndergaard. For details, see *Appendix S2*.

## References

1. Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats A. Global burden of heart failure: a comprehensive and updated review of epidemiology. *Cardiovasc Res.* 2022; **118**: 3272–3287.
2. Ponikowski P, Anker SD, AlHabib KF, Cowie MR, Force TL, Hu S, Jaarsma T, Krum H, Rastogi V, Rohde LE, Samal UC, Shimokawa H, Budi Siswanto B, Sliwa K, Filippatos G. Heart failure: preventing disease and death worldwide. *ESC Heart Fail.* 2014; **1**: 4–25.
3. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skielund A. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J.* 2021; **42**: 3599–3726.
4. Forman DE, Maurer MS, Boyd C, Brindis R, Salive ME, Horne FM, Bell SP, Fulmer

The following authors declare they have no conflicts of interest: Christine Zelenak, Jonas Nagel, Kristina Bersch, Lisa Derendorf, Frank Doyle, Birgit Herbeck Belnap, Sebastian Kohlmann, Carlos A. Velasco, Thomas Asendorf, Christian Axel Bang, Margarita Beresnevaite, Matthew M. Burg, Sussi Friis Buhl, Peter H. Gæde, Anna Markser, Klaudia Vivien Nagy, Chiara Rafanelli, Sanne Rasmussen, Jan Sørensen, Adrienne Stauder, Stephanie Stock, Stefano Urbinati, Diego Della Riva, Rolf Wachter and Florian Walker.

See *Appendix S2* for information on role of funders and legal sponsor in study design, trial governance, trial registration, data safety and monitoring board, ethics advisory board, availability of data and materials, and declaration of interest.

## Funding



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement no. 945377 (ESCAPE). This output reflects the views of the authors, and the European Commission is not responsible for any use that may be made of the information contained therein.

The University of Göttingen Medical Center serves the legal role of a study sponsor. We acknowledge support by the Open Access Publication Funds of the Göttingen University.

## Supporting information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**Appendix S1.** Table “ESCAPE consortium”.

**Appendix S2.** ESCAPE study.

- T, Reuben DB, Zieman S, Rich MW. Multimorbidity in older adults with cardiovascular disease. *J Am Coll Cardiol*. 2018; **71**: 2149–2161.
5. Ladwig K-H, Baghai TC, Doyle F, Hamer M, Herrmann-Lingen C, Kunschitz E, Lemogne C, Beresnevaite M, Compare A, von Känel R, Sager HB, Kop WJ. Mental health-related risk factors and interventions in patients with heart failure: a position paper endorsed by the European Association of Preventive Cardiology (EAPC). *Eur J Prev Cardiol*. 2022; **29**: 1124–1141.
  6. Skou ST, Mair FS, Fortin M, Guthrie B, Nunes BP, Miranda JJ, Boyd CM, Pati S, Mtenga S, Smith SM. Multimorbidity. *Nat Rev Dis Primers*. 2022; **8**: 48.
  7. Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ. Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. *J Am Coll Cardiol*. 2006; **48**: 1527–1537.
  8. Gostoli S, Roncuzzi R, Urbinati S, Morisky DE, Rafanelli C. Unhealthy behaviour modification, psychological distress, and 1-year survival in cardiac rehabilitation. *Br J Health Psychol*. 2016; **21**: 894–916.
  9. Cserép Z, Losonczi E, Balog P, Szili-Török T, Husz A, Juhász B, Kertai MD, Gál J, Székely A. The impact of preoperative anxiety and education level on long-term mortality after cardiac surgery. *J Cardiothorac Surg*. 2012; **7**: 86.
  10. Brown MT, Bussell J, Dutta S, Davis K, Strong S, Mathew S. Medication adherence: truth and consequences. *Am J Med Sci*. 2016; **351**: 387–399.
  11. Which priorities for a European policy on multimorbidity? Conference organized by the EU Commission., 2015.
  12. Avaldi VM, Lenzi J, Urbinati S, Molinazzi D, Descovich C, Campagna A, Taglioni M, Fioritti A, Fantini MP. Effect of cardiologist care on 6-month outcomes in patients discharged with heart failure: results from an observational study based on administrative data. *BMJ Open*. 2017; **7**: e018243.
  13. Damarell RA, Morgan DD, Tieman JJ. General practitioner strategies for managing patients with multimorbidity: a systematic review and thematic synthesis of qualitative research. *BMC Fam Pract*. 2020; **21**: 131.
  14. Oscanoa TJ, Lizaraso F, Carvajal A. Hospital admissions due to adverse drug reactions in the elderly. A meta-analysis. *Eur J Clin Pharmacol*. 2017; **73**: 759–770.
  15. Dechanont S, Maphanta S, Butthum B, Kongkaew C. Hospital admissions/visits associated with drug–drug interactions: a systematic review and meta-analysis. *Pharmacoepidemiol Drug Saf*. 2014; **23**: 489–497.
  16. Rollman BL, Anderson AM, Rothenberger SD, Abebe KZ, Ramani R, Muldoon MF, Jakicic JM, Herbeck Belnap B, Karp JF. Efficacy of blended collaborative care for patients with heart failure and comorbid depression: a randomized clinical trial. *JAMA Intern Med*. 2021; **181**: 1369–1380.
  17. Tully PJ, Selkow T, Bengel J, Rafanelli C. A dynamic view of comorbid depression and generalized anxiety disorder symptom change in chronic heart failure: the discrete effects of cognitive behavioral therapy, exercise, and psychotropic medication. *Disabil Rehabil*. 2015; **37**: 585–592.
  18. Tully PJ, Baumeister H. Collaborative care for comorbid depression and coronary heart disease: a systematic review and meta-analysis of randomised controlled trials. *BMJ Open*. 2015; **5**: e009128.
  19. Carney RM, Freedland KE, Steinmeyer BC, Rubin EH, Ewald G. Collaborative care for depression symptoms in an outpatient cardiology setting: a randomized clinical trial. *Int J Cardiol*. 2016; **219**: 164–171.
  20. Katon WJ, Lin EHB, von Korff M, Ciechanowski P, Ludman EJ, Young B, Peterson D, Rutter CM, McGregor M, McCulloch D. Collaborative care for patients with depression and chronic illnesses. *N Engl J Med*. 2010; **363**: 2611–2620.
  21. Katon W, Russo J, Lin EHB, Schmittdiel J, Ciechanowski P, Ludman E, Peterson D, Young B, von Korff M. Cost-effectiveness of a multicondition collaborative care intervention: a randomized controlled trial. *Arch Gen Psychiatry*. 2012; **69**: 506–514.
  22. Herbeck Belnap B, Anderson A, Abebe KZ, Ramani R, Muldoon MF, Karp JF, Rollman BL. Blended collaborative care to treat heart failure and comorbid depression: rationale and study design of the hopeful heart trial. *Psychosom Med*. 2019; **81**: 495–505.
  23. Mucbe-Borowski C, Lühmann D, Schäfer I, Mundt R, Wagner H-O, Scherer M. Development of a meta-algorithm for guiding primary care encounters for patients with multimorbidity using evidence-based and case-based guideline development methodology. *BMJ Open*. 2017; **7**: e015478.
  24. Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin JA, Doré CJ, Parulekar WR, Summerskill WSM, Groves T, Schulz KF, Sox HC, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 statement: defining standard protocol items for clinical trials. *Ann Intern Med*. 2013; **158**: 200–207.
  25. Mahoney FI, Barthel DW. Functional evaluation: the Barthel index. *Md State Med J*. 1965; **14**: 61–65.
  26. Lübke N, Meinck M, von Renteln-Kruse W. Der Barthel-index in der Geriatrie. Eine Kontextanalyse zum hamburger Einstufungsmanual. [the Barthel index in geriatrics. A context analysis for the Hamburg classification manual]. *Z Gerontol Geriatr*. 2004; **37**: 316–326.
  27. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc*. 2005; **53**: 695–699.
  28. Dobson F, Hinman RS, Hall M, Terwee CB, Roos EM, Bennell KL. Measurement properties of performance-based measures to assess physical function in hip and knee osteoarthritis: a systematic review. *Osteoarthr Cartil*. 2012; **20**: 1548–1562.
  29. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *Qual Life Res*. 2011; **20**: 1727–1736.
  30. Janssen MF, Pickard AS, Golicki D, Gudex C, Niewada M, Scalone L, Swinburn P, Busschbach J. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. *Qual Life Res*. 2013; **22**: 1717–1727.
  31. Spertus JA, Jones PG. Development and validation of a short version of the Kansas city cardiomyopathy questionnaire. *Circ Cardiovasc Qual Outcomes*. 2015; **8**: 469–476.
  32. Tubach F, Ravaud P, Beaton D, Boers M, Bombardier C, Felson DT, van der Heijde D, Wells G, Dougados M. Minimal clinically important improvement and patient acceptable symptom state for subjective outcome measures in rheumatic disorders. *J Rheumatol*. 2007; **34**: 1188–1193.
  33. Tubach F, Ravaud P, Baron G, Falissard B, Logeart I, Bellamy N, Bombardier C, Felson D, Hochberg M, van der Heijde D, Dougados M. Evaluation of clinically relevant states in patient reported outcomes in knee and hip osteoarthritis: the patient acceptable symptom state. *Ann Rheum Dis*. 2005; **64**: 34–37.
  34. Papachristou E, Wannamethee SG, Lennon LT, Papacosta O, Whincup PH, Iliffe S, Ramsay SE. Ability of self-reported frailty components to predict incident disability, falls, and all-cause mortality: results from a population-based study of older British men. *J Am Med Dir Assoc*. 2017; **18**: 152–157.
  35. Luck T, Luppä M, Matschinger H, Jessen F, Angermeyer MC, Riedel-Heller SG. Incident subjective memory complaints and the risk of subsequent dementia. *Acta Psychiatr Scand*. 2015; **131**: 290–296.
  36. Rose M, Björner JB, Becker J, Fries JF, Ware JE. Evaluation of a preliminary physical function item bank supported the expected advantages of the patient-reported outcomes measurement information system (PROMIS). *J Clin Epidemiol*. 2008; **61**: 17–33.
  37. Hurtig-Wennlöf A, Hagströmer M, Olsson LA. The international physical activity questionnaire modified for the el-

- derly: aspects of validity and feasibility. *Public Health Nutr.* 2010; **13**: 1847–1854.
38. Chan AHY, Horne R, Hankins M, Chisari C. The medication adherence report scale: a measurement tool for eliciting patients' reports of nonadherence. *Br J Clin Pharmacol.* 2020; **86**: 1281–1288.
  39. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis.* 1987; **40**: 373–383.
  40. Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, Januel J-M, Sundararajan V. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. *Am J Epidemiol.* 2011; **173**: 676–682.
  41. Dolgin M, Association NYH, Fox AC, Gorlin R, Levin RI, New York Heart Association, Criteria Committee. *Nomenclature and criteria for diagnosis of diseases of the heart and great vessels*, 9th ed. Boston: Lippincott Williams and Wilkins; 1994.
  42. Kroenke K, Spitzer RL, Williams JBW, Löwe B. An ultra-brief screening scale for anxiety and depression: the PHQ-4. *Psychosomatics.* 2009; **50**: 613–621.
  43. iMTA Productivity and Health Research Group. Manual iMTA medical cost questionnaire (iMCA). 2018. [www.imta.nl](http://www.imta.nl). [Accessed 9 February 2023]
  44. iMTA Productivity and Health Research Group. Manual of the iMTA productivity cost questionnaire (iPCQ). 2020. [www.imta.nl](http://www.imta.nl). [Accessed 9 February 2023]
  45. ENRICHD Consortium. Enhancing recovery in coronary heart disease (ENRICHD) study intervention: rationale and design. *Psychosom Med.* 2001; **63**: 747–755.
  46. Vaglio J, Conard M, Poston WS, O'Keefe J, Haddock CK, House J, Spertus JA. Testing the performance of the ENRICHD social support instrument in cardiac patients. *Health Qual Life Outcomes.* 2004; **2**: 24.
  47. Russell D, Peplau LA, Ferguson ML. Developing a measure of loneliness. *J Pers Assess.* 1978; **42**: 290–294.
  48. O'Suilleabháin PS, Gallagher S, Steptoe A. Loneliness, living alone, and all-cause mortality: the role of emotional and social loneliness in the elderly during 19 years of follow-up. *Psychosom Med.* 2019; **81**: 521–526.
  49. Romppel M, Herrmann-Lingen C, Wachter R, Edelmann F, Düngen H-D, Pieske B, Grande G. A short form of the general self-efficacy scale (GSE-6): development, psychometric properties and validity in an intercultural non-clinical sample and a sample of patients at risk for heart failure. *Psychosom Med.* 2013; **10**: Doc01.
  50. Schwarzer R, Jerusalem M. Generalized self-efficacy scale. In Weinman J, Wright S, Johnston M., eds. *Measures in health psychology: A user's portfolio. Causal and control beliefs*, Vol. 1995. Windsor, England: NFER-NELSON; 1995. p 35–37.
  51. Webster K, Cella D, Yost K. The functional assessment of chronic illness therapy (FACIT) measurement system: properties, applications, and interpretation. *Health Qual Life Outcomes.* 2003; **1**: 79.
  52. Haun J, Luther S, Dodd V, Donaldson P. Measurement variation across health literacy assessments: implications for assessment selection in research and practice. *J Health Commun.* 2012; **17**: 141–159.
  53. Broadbent E, Petrie KJ, Main J, Weinman J. The brief illness perception questionnaire. *J Psychosom Res.* 2006; **60**: 631–637.
  54. Alberts J, Löwe B, Glahn MA, Petrie K, Laferton J, Nestoriuc Y, Shedden-Mora M. Development of the generic, multidimensional treatment expectation questionnaire (TEX-Q) through systematic literature review, expert surveys and qualitative interviews. *BMJ Open.* 2020; **10**: e036169.
  55. Duncan P, Murphy M, Man M-S, Chaplin K, Gaunt D, Salisbury C. Development and validation of the multimorbidity treatment burden questionnaire (MTBQ). *BMJ Open.* 2018; **8**: e019413.
  56. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. *J Health Soc Behav.* 1983; **24**: 385–396.
  57. Ingram PB, Clarke E, Lichtenberg JW. Confirmatory factor analysis of the perceived stress scale-4 in a community sample. *Stress Health.* 2016; **32**: 173–176.
  58. Hatcher RL, Gillaspay JA. Development and validation of a revised short version of the working alliance inventory. *Psychother Res.* 2006; **16**: 12–25.
  59. Brouwer WBF, van Exel NJA, van Gorp B, Redekop WK. The CarerQol instrument: a new instrument to measure care-related quality of life of informal caregivers for use in economic evaluations. *Qual Life Res.* 2006; **15**: 1005–1021.
  60. Novak M, Guest C. Application of a multidimensional caregiver burden inventory. *Gerontologist.* 1989; **29**: 798–803.
  61. Diener E, Emmons RA, Larsen RJ, Griffin S. The satisfaction with life scale. *J Pers Assess.* 1985; **49**: 71–75.
  62. Hughes ME, Waite LJ, Hawkey LC, Cacioppo JT. A short scale for measuring loneliness in large surveys: results from two population-based studies. *Res Aging.* 2004; **26**: 655–672.
  63. Wade J, Donovan JL, Lane JA, Neal DE, Hamdy FC. It's not just what you say, it's also how you say it: opening the 'black box' of informed consent appointments in randomised controlled trials. *Soc Sci Med.* 2009; **68**: 2018–2028.
  64. Mills N, Blazeby JM, Hamdy FC, Neal DE, Campbell B, Wilson C, Paramasivan S, Donovan JL. Training recruiters to randomized trials to facilitate recruitment and informed consent by exploring patients' treatment preferences. *Trials.* 2014; **15**: 323.
  65. Davidson KW, Rieckmann N, Clemow L, Schwartz JE, Shimbo D, Medina V, Albanese G, Kronish I, Hegel M, Burg MM. Enhanced depression care for patients with acute coronary syndrome and persistent depressive symptoms: coronary psychosocial evaluation studies randomized controlled trial. *Arch Intern Med.* 2010; **170**: 600–608.
  66. Rollman BL, Belnap BH, LeMenager MS, Mazumdar S, Houck PR, Counihan PJ, Kapoor WN, Schulberg HC, Reynolds CF. Telephone-delivered collaborative care for treating post-CABG depression: a randomized controlled trial. *JAMA.* 2009; **302**: 2095–2103.
  67. Sadlonova M, Löser JK, Celano CM, Kleiber C, Broschmann D, Herrmann-Lingen C. Changes in treatment outcomes in patients undergoing an integrated psychosomatic inpatient treatment: results from a cohort study. *Front Psych.* 2022; **13**: 964879.
  68. Scherer M, Wagner H-O, Lühmann D, Muche-Borowski C, Schäfer I, Dubben H-H, Hansen H, Thiesemann R, von Renteln-Kruse W, Hofmann W, Fessler J, Bussche H. S3-Leitlinie Multimorbidität. <https://www.awmf.org/leitlinien/detail/ll/053-047.html> 2017. [Accessed 9 February 2023].
  69. Schwaab B, Bjarnason-Wehrens B, Meng K, Albus C, Salzwedel A, Schmid J-P, Benzer W, Metz M, Jensen K, Rauch B, Bönner G, Brzoska P, Buhr-Schinner H, Charrier A, Cordes C, Dörr G, Eichler S, Exner A-K, Fromm B, Gielen S, Glatz J, Gohlke H, Grilli M, Gysan D, Härtel U, Hahmann H, Herrmann-Lingen C, Karger G, Karoff M, Kiwus U, Knoglinger E, Krusch C-W, Langheim E, Mann J, Max R, Metzendorf M-I, Nebel R, Niebauer J, Predel H-G, Preßler A, Razum O, Reiss N, Saure D, von Schacky C, Schütt M, Schultz K, Skoda E-M, Steube D, Streibelt M, Stüttgen M, Stüttgen M, Teufel M, Tschanz H, Völler H, Vogel H, Westphal R. Cardiac rehabilitation in German speaking countries of Europe-evidence-based guidelines from Germany, Austria and Switzerland LLKardReha-DACH-part 2. *J Clin Med.* 2021; **10**: 3071.
  70. Herrmann-Lingen C, Albus C, de Zwaan M, Geiser F, Heinemann K, Hellmich M, Michal M, Sadlonova M, Tostmann R, Wachter R, Herbeck Belnap B. Efficacy of team-based collaborative care for distressed patients in secondary prevention of chronic coronary heart disease (TEACH): study protocol of a multicenter randomized controlled trial. *BMC Cardiovasc Disord.* 2020; **20**: 520.
  71. Bosselmann L, Fangauf SV, Herbeck Belnap B, Chavanon M-L, Nagel J,

- Neitzel C, Schertz A, Hummers E, Wachter R, Herrmann-Lingen C. Blended collaborative care in the secondary prevention of coronary heart disease improves risk factor control: results of a randomised feasibility study. *Eur J Cardiovasc Nurs.* 2020; **19**: 134–141.
72. Herrmann-Lingen C, Zelenak C, Nagel J, Bersch K, Wicker M, Herbeck Belnap B, Friede T, Lühmann D, Ousager J, Stock S, Albus C, Beresnevaite M, Doyle F, McAdam B, Skou S, Stauder A, Urbinati S, Wachter R, Pedersen S. Evaluation of a patient-centred biopsychosocial blended collaborative care pathway for the treatment of multi-morbid elderly patients – the ESCAPE clinical study. *J Psychosom Res.* 2022; **157**: 110857.
73. Kohlmann S, Jaarsma T, Rafanelli C, Andréasson F, Gostoli S, Löwe B, Rasmussen S, Bernardini F, Thilsing T, Eilerskov N, Engelmänn P. Needs of multimorbid elderly with chronic heart failure regarding a blended- collaborative care: a qualitative interview study in preparation of an intervention within the EU project ESCAPE. *J Psychosom Res.* 2022; **157**: 110871.
74. Harris MF, Dennis S, Pillay M. Multimorbidity: negotiating priorities and making progress. *Aust Fam Physician.* 2013; **42**: 850–854.
75. O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. *Age Ageing.* 2015; **44**: 213–218.
76. Michie S, Richardson M, Johnston M, Abraham C, Francis J, Hardeman W, Eccles MP, Cane J, Wood CE. The behavior change technique taxonomy (v1) of 93 hierarchically clustered techniques: building an international consensus for the reporting of behavior change interventions. *Ann Behav Med.* 2013; **46**: 81–95.
77. Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, Altman DG, Barbour V, Macdonald H, Johnston M, Lamb SE, Dixon-Woods M, McCulloch P, Wyatt JC, Chan A-W, Michie S. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. *BMJ.* 2014; **348**: g1687.
78. Lambert JD, Greaves CJ, Farrand P, Cross R, Haase AM, Taylor AH. Assessment of fidelity in individual level behaviour change interventions promoting physical activity among adults: a systematic review. *BMC Public Health.* 2017; **17**: 765.
79. Ory MG, Jordan PJ, Bazzarre T. The behavior change consortium: setting the stage for a new century of health behavior-change research. *Health Educ Res.* 2002; **17**: 500–511.
80. <https://ec.europa.eu/cefdigital/wiki/display/CEFDIGITAL/German+-+eTranslation+for+SMEs>
81. Smith SM, Wallace E, Salisbury C, Sasseville M, Bayliss E, Fortin M. A core outcome set for multimorbidity research (COSmm). *Ann Fam Med.* 2018; **16**: 132–138.
82. Mercer SW, Fitzpatrick B, Guthrie B, Fenwick E, Grieve E, Lawson K, Boyer N, McConnachie A, Lloyd SM, O'Brien R, Watt GCM, Wyke S. The CARE plus study - a whole-system intervention to improve quality of life of primary care patients with multimorbidity in areas of high socioeconomic deprivation: exploratory cluster randomised controlled trial and cost-utility analysis. *BMC Med.* 2016; **14**: 88.
83. Shah V, Stokes J, Sutton M. Effects of non-medical health coaching on multimorbid patients in primary care: a difference-in-differences analysis. *BMC Health Serv Res.* 2019; **19**: 593.
84. ten Haaf DSM, van Dongen EJI, Nuijten MAH, Eijssvogels TMH, de Groot LCPGM, Hopman MTE. Protein intake and distribution in relation to physical functioning and quality of life in community-dwelling elderly people: acknowledging the role of physical activity. *Nutrients.* 2018; **10**: 506.
85. McMahon SE, Diamond OJ, Cusick LA. Coned hemipelvis reconstruction for osteoporotic acetabular fractures in frail elderly patients. *Bone Joint J.* 2020; **102-B**: 155–161.
86. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand.* 1983; **67**: 361–370.
87. Herrmann-Lingen C, Buss U, Snaith RP. HADS-D. Hospital anxiety and depression scale-Deutsche Version. Deutsche Adaptation der Hospital Anxiety and Depression Scale (HADS) von R. P. Snaith und A. S. Zigmond.: 4. Aktualisierte Auflage. In: Bern: Hogrefe; 2018.
88. Herrmann C. International experiences with the hospital anxiety and depression scale—a review of validation data and clinical results. *J Psychosom Res.* 1997; **42**: 17–41.
89. Schulze J, Glassen K, Pohontsch NJ, Blozik E, Eißing T, Breckner A, Höflich C, Rakebrandt A, Schäfer I, Szecsenyi J, Scherer M, Lühmann D. Measuring the quality of care for older adults with multimorbidity: results of the MULTiqual project. *Gerontologist.* 2022; **62**: 1135–1146.
90. Blozik E, Lühmann D, Scherer M. Entwicklung und Validierung von Qualitätsindikatoren für Multimorbidität: Medizinisch Wissenschaftliche Verlagsgesellschaft 2017(7):380–6.
91. Pohontsch NJ, Schulze J, Höflich C, Glassen K, Breckner A, Szecsenyi J, Lühmann D, Scherer M. Quality of care for people with multimorbidity: a focus group study with patients and their relatives. *BMJ Open.* 2021; **11**: e047025.
92. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials|annals of internal medicine. 2021. <https://www.acpjournals.org/doi/pdf/10.7326/0003-4819-152-11-201006010-00232>. [Accessed 27 May 2021].
93. Huffman JC, Mastromauro CA, Beach SR, Celano CM, DuBois CM, Healy BC, Suarez L, Rollman BL, Januzzi JL. Collaborative care for depression and anxiety disorders in patients with recent cardiac events: the Management of Sadness and Anxiety in cardiology (MOSAIC) randomized clinical trial. *JAMA Intern Med.* 2014; **174**: 927–935.
94. Katon W, Lin EHB, von Korff M, Ciechanowski P, Ludman E, Young B, Rutter C, Oliver M, McGregor M. Integrating depression and chronic disease care among patients with diabetes and/or coronary heart disease: the design of the TEAMcare study. *Contemp Clin Trials.* 2010; **31**: 312–322.
95. Triposkiadis F, Giamouzis G, Parissis J, Starling RC, Boudoulas H, Skoularigis J, Butler J, Filippatos G. Reframing the association and significance of co-morbidities in heart failure. *Eur J Heart Fail.* 2016; **18**: 744–758.
96. Schmoor C, Olschewski M, Schumacher M. Randomized and non-randomized patients in clinical trials: experiences with comprehensive cohort studies. *Stat Med.* 1996; **15**: 263–271.
97. Röver C, Friede T. Dynamically borrowing strength from another study through shrinkage estimation. *Stat Methods Med Res.* 2020; **29**: 293–308.
98. Hussey AJ, McKelvie RS, Ferrone M, To T, Fisk M, Singh D, Faulds C, Licskai C. Primary care-based integrated disease management for heart failure: a study protocol for a cluster randomised controlled trial. *BMJ Open.* 2022; **12**: e058608.